In a patient with rheumatic heart disease and severe mitral stenosis who is status post above‑knee amputation, what is the recommended evaluation and management?

Management of Severe Rheumatic Mitral Stenosis in Post-Above-Knee Amputation Patient

This patient requires immediate comprehensive echocardiographic evaluation to determine intervention candidacy, with percutaneous mitral balloon commissurotomy (PMBC) as the preferred intervention if valve morphology is favorable, or surgical mitral valve replacement if not—the amputation status does not contraindicate either approach but increases surgical risk assessment considerations. 1, 2

Initial Evaluation Algorithm

Echocardiographic Assessment (Priority #1)

Obtain both transthoracic and transesophageal echocardiography to assess:

• Mitral valve area (severe MS defined as MVA ≤1.5 cm²) 2
• Valve morphology score for PMBC suitability (Wilkins score or Cormier score) 2
• Commissural fusion pattern, leaflet thickening, restricted mobility, calcification degree 3
• Subvalvular apparatus involvement (chordal thickening/fusion) 2
• Mitral regurgitation severity (>moderate MR makes PMBC less suitable) 2
• Left atrial size and presence of thrombus (absolute contraindication to PMBC) 2
• Pulmonary artery systolic pressure (PASP >50 mmHg indicates advanced disease) 2
• Right ventricular function and tricuspid regurgitation severity 1

Symptom and Functional Status Assessment

Document:

• NYHA functional class (this patient likely NYHA III-IV given severe MS) 2
• Exercise tolerance limitations beyond those from amputation
• Presence of orthopnea, paroxysmal nocturnal dyspnea, pulmonary edema 2

Cardiac Rhythm Evaluation

• ECG to assess for atrial fibrillation 1, 2
• If AF present: mandatory anticoagulation with vitamin K antagonist (warfarin) targeting INR 2-3 for rheumatic MS—NOACs are contraindicated in this specific population 1, 2
• If sinus rhythm with history of systemic embolism or LA thrombus: still requires warfarin 2

Intervention Decision Pathway

For Symptomatic Severe MS (NYHA II-IV with MVA ≤1.5 cm²):

PMBC is first-line if favorable characteristics present: 2

• Echocardiographic score ≤8
• Commissural fusion as predominant mechanism
• Less than moderate mitral regurgitation
• No left atrial thrombus
• Absence of heavy calcification or severe subvalvular disease

Proceed directly to surgery if unfavorable for PMBC: 2

• Echocardiographic score >8 or Cormier score 3
• Heavily calcified valve
• Severe subvalvular involvement
• Moderate-to-severe mitral regurgitation
• Left atrial thrombus present (despite anticoagulation)

Amputation-Specific Considerations

The above-knee amputation status affects risk stratification but does not change the fundamental indication for intervention:

• Surgical risk assessment: Calculate EuroSCORE II or STS-PROM score 2
• The amputation increases rehabilitation complexity but does not constitute "futility" unless life expectancy <1 year or patient is poor candidate for any rehabilitation 2
• PMBC becomes relatively more attractive in this patient given lower procedural risk compared to surgery with cardiopulmonary bypass in someone with altered mobility
• If surgical risk score >15% or patient has multiple comorbidities, strongly favor PMBC even with suboptimal anatomy 2

Medical Management (Bridging or Adjunctive)

Heart Rate Control

• Beta-blockers (metoprolol, carvedilol) as first-line for rate control 2
• Add ivabradine if sinus rhythm with inadequate rate control 2
• Calcium channel blockers (diltiazem, verapamil) if beta-blockers contraindicated 2

Volume Management

• Diuretics (furosemide) for pulmonary congestion symptoms 2
• Careful monitoring given potential for hypotension with fixed cardiac output from MS

Anticoagulation (Critical)

• Warfarin INR 2-3 is mandatory if AF present or history of embolism 1, 2
• Consider warfarin even in sinus rhythm if severe LA enlargement or spontaneous echo contrast 2

Multidisciplinary Heart Team Evaluation

All patients with severe valvular disease require evaluation by a multidisciplinary team at a Primary or Comprehensive Valve Center 1, 2. This is particularly important given:

• Complex risk assessment with amputation
• Need for coordinated perioperative rehabilitation planning
• Determination of optimal intervention timing and modality

Post-Intervention Surveillance

After PMBC:

• Immediate post-procedure TEE to assess results and exclude complications 3
• Monitor for restenosis (repeat PMBC possible if commissural refusion is mechanism) 2

After Surgery:

• Higher risk of complications given amputation and mobility limitations 4
• Intensive rehabilitation coordination
• Lifelong warfarin if mechanical valve (INR 2.5-3.5) 1

Critical Pitfalls to Avoid

1. Do not use NOACs in rheumatic MS with AF—only warfarin is appropriate 1, 2
2. Do not delay intervention waiting for "optimal" surgical candidacy—progressive pulmonary hypertension becomes irreversible 5
3. Do not dismiss PMBC candidacy based solely on age or comorbidities if valve morphology is favorable 2
4. Do not perform intervention without TEE to exclude LA thrombus 2
5. Do not assume amputation equals surgical futility—assess functional capacity and rehabilitation potential objectively 2

The amputation complicates but does not preclude definitive treatment; PMBC should be strongly considered as first-line given lower procedural risk in this already mobility-compromised patient, provided valve morphology permits 2.